Podcasts about Vertex

Luck of the Irish.   Irish international amateur golfer David Howard  doesn't seem to need luck with all the talent he has. We had an inspiring conversation about chasing big dreams while living with cystic fibrosis. When we recorded this podcast David had not yet qualified for the Open Championship.  He did qualify just after we recorded and went on to play. Quoting from the Open Championship paper, "On the course, Howard more than held his own alongside the world's best. He started with a four-over-par 74 before finding his groove on Friday. A birdie at the 11th was his fourth of the day and took him to +2, within sight of the cut line. Howard ultimately missed out, dropping a shot at 14 to finish three-over for his week, but took heart from his display." Bravo David!  You're an inspiration.  David shares his journey growing up in Cork, Ireland, where he was diagnosed with CF at the age of seven and learned to balance daily treatments, hospital stays, and the demands of competitive golf. He also explains how his golfing journey began with Pitch and Putt, a sport similar to golf that features shorter holes and requires just a few clubs. The game helped him develop his skills and passion before transitioning to competitive golf. David talks about how advances in CF care have transformed his health, allowing him to compete at the highest levels of amateur golf while representing Ireland on the international stage. The conversation explores David's breakthrough victories, including winning the prestigious East of Ireland Amateur Championship, his ambitions of turning professional, and the discipline and mental resilience required to compete in elite sports. He also shares practical tips on how he stays mentally focused during a golf tournament, manages pressure, and keeps his confidence throughout competition. David reflects on the important role his family, coaches, and teammates have played throughout his journey. Beyond golf, David opens up about the emotional side of living with cystic fibrosis, the importance of talking openly about chronic illness and mental health, and why he is passionate about raising awareness through fundraising and advocacy. He also shares his hopes of writing a book one day and inspiring the next generation of young people living with CF to believe that their diagnosis does not have to define their future. Whether you're a golf fan, part of the cystic fibrosis community, or simply love stories of perseverance, this episode is a reminder that determination, support, and advances in medicine can make extraordinary dreams possible. David is an ambassador for Cystic Fibrosis Ireland. https://www.cfireland.ie Thanks to Nicola Delaney-Foxe for connecting us! Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

הפרק הוקלט במסגרת אירוע לייב של מהדורת מוסף. לקבלת עדכונים על האירוע הבא הצטרפו לקבוצה הסגורה שלנו.משה שלו, מייסד-שותף ב-Decart, מגיע לשיחה מרתקת על בניית אחת מחברות ה-AI השאפתניות בישראל, שמפתחת מודלי וידאו בזמן אמת ומתחרה בחברות כמו OpenAI וגוגל.בשיחה ​​בהנחיית ​עמית קרפ ​ (Bessemer​), ברק שוסטר (Battery)​,​ ינאי אורון (Vertex) וגיא קצוביץ' (Fusion)​ - משה מסביר מדוע העתיד של הבינה המלאכותית נמצא דווקא במודלי וידאו וב-Physical AI, חושף את המודל העסקי שמאפשר לחברה לייצר הכנסות מאופטימיזציה של תשתיות AI, ומשתף בהחלטה האסטרטגית לוותר על מוצרי B2C ולהתמקד בבניית תשתיות עמוקות לעולם הבינה המלאכותית.משה מדבר על חשיבות השארת הטאלנט הישראלי בחזית החדשנות, התחרות מול ענקיות הטכנולוגיה, והחזון לעתיד שבו רובוטים יהפכו לחלק בלתי נפרד מחיי היומיום שלנו(00:00:00) הצגת חברת Decart ופיתוח מודלי וידאו בזמן אמת(00:02:16) העתיד של מודלי הווידאו: מעולמות הבידור לרובוטיקה (Physical AI)(00:04:03) בניית חברת מודלים מובילה מישראל והתחרות על טאלנטים(00:07:11) המודל העסקי: איך עושים כסף מאופטימיזציה של צ'יפים ותשתיות?(00:09:11) למה Decart החליטה להקפיא את פיתוחי ה-B2C לטובת מודלים ותשתיות(00:12:19) החזון לעתיד: גיימינג מול הכנסת רובוטים הביתה(00:18:04) חשיבות הפיתוח של מודלי AI מתקדמים בישראל אל מול תעשיית הסייבר

הפרק הוקלט במסגרת אירוע לייב של מהדורת מוסף. לקבלת עדכונים על האירוע הבא הצטרפו לקבוצה הסגורה שלנו.שי לוי, מנכ"ל Unframe ויזם סדרתי ​(שכבר רשם אקזיט משמעותי עם Noname​), מגיע לשיחה כנה על האתגרים שבבניית חברת AI בעידן שבו השוק משתנה בקצב חסר תקדים.בשיחה ​​בהנחיית ​עמית קרפ ​ (Bessemer​), ברק שוסטר (Battery)​,​ ינאי אורון (Vertex) וגיא קצוביץ' (Fusion)​ - שי משתף במטען הנפשי שמלווה הקמת חברה שנייה, מסביר מדוע בחרו לוותר על מוצר אחד לטובת בניית מאות פתרונות AI מותאמים אישית לארגוני ענק, ואיך המודל הייחודי הזה מאפשר להם לסגור עסקאות בתוך שבועות ספורים.בנוסף, שי מנתח את עתיד שוק התוכנה, בוחן האם עידן ה-SaaS מתקרב לנקודת מפנה, ומסביר מתי חברות שאינן טכנולוגיות עשויות להפסיק להחזיק צוותי פיתוח פנימיים ולעבור לעולם חדש של תוכנות מבוססות AI.(00:00:00) פתיחה ואיך זה להיות מנכ"ל בחזית(00:03:27) המחיר הנפשי במסע של יזם סדרתי(00:07:34) המודל העסקי של Unframe ו"המסעדה הסינית"(00:10:06) מכירות AI לאנטרפרייז בחודש וחצי(00:14:11) בניית אמון (Trust) מול ארגוני ענק(00:16:26) עתיד חברות ה-SaaS מול מערכות AI פנימיות(00:19:10) מדוע סטארבקס לא צריכה צוותי R&D?(*) לאינסטגרם של גיא: https://www.instagram.com/guykatsovich/"האופטימייזר" בהנחיית גיא קצוביץ' מופק ע"י Valuebell - בית הפקות לפודקאסטים.

Dreams and Determination: Meet four Inspiring students, Living with cystic fibrosis. One of the greatest joys of The Bonnell Foundation is helping young adults living with cystic fibrosis pursue their educational dreams. Every year, we award scholarships to students attending universities, trade schools, and community colleges. While these scholarships help with tuition and expenses, they also send an important message: we believe in these students and in the futures they are building. Living with cystic fibrosis often means balancing classes, careers, friendships, and family life alongside daily treatments, medications, and frequent medical appointments. For many families, the financial burden of CF can make the cost of higher education even more challenging. That's why our scholarship program is so meaningful. Each year, our top recipients receive $2,500 to help them continue their education and pursue their goals. The thank-you notes we receive from recipients are heartfelt reminders that a scholarship is about much more than money. It is about hope, opportunity, and encouragement. On this week's podcast, we are honored to introduce four remarkable scholarship recipients whose determination and resilience inspire us. Serena Scillia is a 20-year-old from Westerville, Ohio, attending Bowling Green State University. Serena is studying Early Childhood Education and hopes to become a teacher. When she's not focused on her studies, she enjoys coaching volleyball, reading, and spending time with her family and beloved dog. Serena's passion for helping others shines through in her career choice, and she's determined to make a difference in the lives of children. Jayla Jacobs has been living with cystic fibrosis since she was diagnosed at age five. Now 18 years old, she has already become a powerful advocate for the CF community. Jayla has spoken at multiple fundraising and awareness events, including the Cystic Fibrosis Foundation's Guys and Dolls Auction Gala, where she helped raise an incredible $2.2 million for CF research. This fall, she will begin studying English at North Carolina State University. Jayla loves outdoor adventures, drawing, and writing stories. She also understands the impact of CF on families, with two of her brothers living with the disease as well. Isabella Banaszynski is preparing for an exciting new chapter as she heads to Drexel University in Philadelphia this fall. An accomplished club wrestler and aspiring architect, Isabella has already demonstrated the discipline and determination needed to succeed in demanding environments. She plans to major in Architecture while continuing to pursue her athletic interests. Isabella's journey is proof that living with CF does not define what is possible. Ben Ferguson attends Taylor University and is majoring in Finance. Originally from Columbus, Indiana, Ben comes from a large family with four brothers and one sister. While he is the only member of his family living with cystic fibrosis, he has never allowed the disease to limit his ambitions. Ben is focused on building a successful future while managing the daily challenges that come with CF. These four young adults represent the strength, perseverance, and optimism that define so many people in the cystic fibrosis community. Their stories remind us that while CF can create obstacles, it does not determine a person's potential. Join us on this week's podcast as Serena, Jayla, Isabella, and Ben share their experiences living with cystic fibrosis, pursuing higher education, and what receiving a Bonnell Foundation scholarship means to them. Their stories are inspiring, their goals are ambitious, and their futures are bright. This is exactly why The Bonnell Foundation continues its scholarship program year after year: to invest in dreams, support determination, and help the next generation of leaders living with cystic fibrosis reach their full potential. Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

What if the biggest obstacle to AI-driven ROI isn't the AI itself, but everything you're feeding it?Agility requires not just the speed to adopt new technologies like AI, but the clarity to recognize when foundational elements, like your data strategy, must be fixed first to unlock true potential.Today, we're going to talk about the intense pressure on revenue and marketing leaders to demonstrate ROI from AI. We'll explore the counterintuitive idea that simply chasing 'better AI' is a distraction, and that the real gains come from addressing the foundational data gaps that plague most organizations.To help me discuss this topic, I'd like to welcome, Ann Davis, Chief Revenue Officer at Crunchbase. About Ann DavisAnn Davis is the Chief Revenue Officer at Crunchbase, where she leads global sales strategy and drives adoption of the company's AI-powered predictive intelligence solution. With more than 30 years of experience scaling enterprise sales teams at high-growth SaaS companies, Ann brings deep expertise in data analytics, customer engagement, and revenue growth. She joined Crunchbase from Google Cloud, where she led sales for data analytics solutions—including BigQuery and Vertex—across multiple U.S. regions. Prior to that, she was Vice President of Sales at Looker, playing a key role in expanding its enterprise business ahead of its acquisition by Google. At Crunchbase, Ann is focused on helping customers unlock the power of AI-driven market insights to anticipate shifts and act faster.Ann Davis on LinkedIn: https://www.linkedin.com/in/anndavis3/---------- Resources ---------- Crunchbase: https://www.crunchbase.comThe Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://aglbrnd.co/r/2868abd8085a9703We're proud to be a media partner for #MAICON26 - Oct. 13-15! Learn how AI can power your marketing and business and help you grow smarter. Use code AGILE150 to save! https://aglbrnd.co/r/7fe458ced0f04658Reach your customers with Reddit. Spend $500 in ad spend, get $500 back in ad credit! Learn more: https://advertalize.com/r/491818c79fb1873fChaser is the only Slack-native project management platform that helps teams turn messages into tracked tasks, automate follow-ups, and maintain team-wide visibility, without adopting another tool. Now integrated with Claude and other GenAI tools. Learn more at trychaser.com and use code AGILEBRAND for a 3-month free trial (normal trial is 14 days).The most influential minds in software, AI, and engineering leadership will be at WeAreDevelopers World Congress North America, September 23-25 in San Jose. Learn more: https://aglbrnd.co/r/60a7299222a7bcf1Enjoyed the show? Tell us more at and give us a rating so others can find the show at: https://aglbrnd.co/r/faaed112fc9887f3Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstromDon't miss a thing: get the latest episodes, sign up for our newsletter and more: https://aglbrnd.co/r/35ded3ccfb6716baCheck out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.comThe Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company Hosted on Acast. See acast.com/privacy for more information.

This week on "The Top Line," we’re covering some of the biggest stories across biopharma before turning to one of the industry’s major scientific meetings of the summer. First, we discuss Vertex’s $10 billion acquisition of Crinetics Pharmaceuticals, the company’s largest deal to date, and what it says about Vertex’s push beyond its historic strength in cystic fibrosis. We also cover growing scrutiny from U.S. lawmakers over the industry’s use of clinical trials in China. Then, Fierce Pharma Senior Editor Fraiser Kansteiner recounts his recent trip to New Orleans for the American Diabetes Association’s 2026 Scientific Sessions with Fierce Pharma Marketing’s Zoey Becker. For years, ADA has focused heavily on its eponymous indication, but this year’s meeting made clear how much the conversation is evolving, with obesity data from drugmakers of all stripes taking up more of the spotlight. Topics include the biggest data sets from the meeting, what it was like to sit down with Novo Nordisk’s new CEO for the first time and the latest from Insulet’s Marvel collaboration on a line of comics about an Omnipod-wearing superheroine. To learn more about the topics in this episode: Vertex, in its largest-ever deal, acquires endocrine disease specialist Crinetics for $10B As US lawmakers increase scrutiny of Chinese trials, industry fears ‘huge distraction and expense’ ‘I’m a lot more optimistic today’: Mike Doustdar tells Fierce about pivotal first year as Novo Nordisk CEO ADA: Lilly pulls back curtain on impressive triple-G efficacy in patients with obesity, diabetes ADA: Amgen highlights Repatha perks, GLP-1 pitfalls in push to boost cardiometabolic pedigree With ADA in the books, analyst says Lilly is ‘widening its lead’ in the obesity race ADA: Novo's Wegovy pill reaches new GLP-1 patients with impressive 3M prescription milestone ADA: Tolerability ‘not to be underappreciated’ in Roche, Zealand’s amylin obesity prospect ADA: Boehringer execs claim survodutide tolerability 'consistent' with class despite phase 3 update ADA: Lilly posts oral semaglutide-topping data as Foundayo speeds toward 2nd potential nod in diabetes This week's episode is sponsored by IQVIA Biotech. Built for biotech innovators, IQVIA Biotech is a full-service CRO, designed for agility, fast decisions, and the urgency needed for emerging biopharma. With dedicated teams and deep therapeutic expertise, we help move programs forward with focus and confidence. Visit IQVIABiotech.comSee omnystudio.com/listener for privacy information.

On this week's episode, Sam Fazeli, Josh Schimmer, Eric Schmidt, Paul Matteis, and special guest STAT's Matt Herper open on the market, noting that despite a wobbly day for biotech, the XBI holds strong gains year-to-date. The conversation turns to FDA transparency, where the co-hosts flag that CRLs haven't been released since April and that the agency may be walking back that practice. The co-hosts debate whether the FDA is swinging too far toward leniency after Agios' mitapivat won priority review in sickle cell disease despite missing its primary endpoint last year. On AI in drug discovery, Matt Herper recaps an interview with Anthropic's CEO about a new research tool, noting that it's plausible the tool helps industry pick better targets and lower the failure rate. In M&A, Vertex's largest-ever deal takes Crinetics for $10 billion net of cash, staking a claim in the specialty rare endocrine space, while Novartis expands its ADC portfolio with Myricx for $1.1 billion upfront plus $400 million in milestones — the second European ADC deal in recent months. On data, AstraZeneca and Ionis' eplontersen trial in ATTR-CM missed its endpoint, showing no benefit or biomarker signal on top of background tafamidis; the group then discusses the readthroughs for BridgeBio, Alnylam, and Pfizer's ATTR therapies. This episode aired on July 10, 2026.

International Biotechnology Trust (LSE:IBT) portfolio manager Ailsa Craig joined Proactive's Stephen Gunnion to discuss the surge in biotech M&A activity, following Vertex Pharmaceuticals' acquisition of Crinetics at a 102% premium. Craig said the deal wave reflects a structural dynamic: most new drugs now originate from biotech, while large pharmaceutical companies face a significant wave of patent expiries and hold substantial cash resources. Vertex's move into rare diseases and chronic therapies makes strategic sense as it diversifies beyond its cystic fibrosis franchise — and the premium paid reflected Crinetics' strong independent position. "They would be perfectly happy to stay independent. And Vertex had to pay up if they wanted to buy them," Craig said. She outlined how IBT evaluates investments using many of the same criteria as pharma business development teams — focusing on chronic therapies, attractive valuations, strong intellectual property and companies capable of remaining independent, making them compelling acquisition targets. Around 40% of IBT's portfolio currently meets these criteria, compared with around 10% of its benchmark - a positioning Craig believes leaves the trust well placed to benefit from continued industry consolidation. Visit the Proactive YouTube channel for more interviews with leading companies and investment experts. If you enjoyed this video, please like, subscribe to the channel and enable notifications so you never miss future content. #InternationalBiotechnologyTrust #Biotech #Biotechnology #AilsaCraig #HealthcareInvesting #BiotechStocks #Pharma #Vertex #Crinetics #MergersAndAcquisitions #Investing #StockMarket #LifeSciences #PatentExpiry #HealthcareInnovation #ProactiveInvestors

What if the biggest obstacle to AI-driven ROI isn't the AI itself, but everything you're feeding it?Agility requires not just the speed to adopt new technologies like AI, but the clarity to recognize when foundational elements, like your data strategy, must be fixed first to unlock true potential.Today, we're going to talk about the intense pressure on revenue and marketing leaders to demonstrate ROI from AI. We'll explore the counterintuitive idea that simply chasing 'better AI' is a distraction, and that the real gains come from addressing the foundational data gaps that plague most organizations.To help me discuss this topic, I'd like to welcome, Ann Davis, Chief Revenue Officer at Crunchbase. About Ann DavisAnn Davis is the Chief Revenue Officer at Crunchbase, where she leads global sales strategy and drives adoption of the company's AI-powered predictive intelligence solution. With more than 30 years of experience scaling enterprise sales teams at high-growth SaaS companies, Ann brings deep expertise in data analytics, customer engagement, and revenue growth. She joined Crunchbase from Google Cloud, where she led sales for data analytics solutions—including BigQuery and Vertex—across multiple U.S. regions. Prior to that, she was Vice President of Sales at Looker, playing a key role in expanding its enterprise business ahead of its acquisition by Google. At Crunchbase, Ann is focused on helping customers unlock the power of AI-driven market insights to anticipate shifts and act faster.Ann Davis on LinkedIn: https://www.linkedin.com/in/anndavis3/---------- Resources ---------- Crunchbase: https://www.crunchbase.comThe Agile Brand podcast is brought to you by TEKsystems. Learn more here: https://aglbrnd.co/r/2868abd8085a9703We're proud to be a media partner for #MAICON26 - Oct. 13-15! Learn how AI can power your marketing and business and help you grow smarter. Use code AGILE150 to save! https://aglbrnd.co/r/7fe458ced0f04658Reach your customers with Reddit. Spend $500 in ad spend, get $500 back in ad credit! Learn more: https://advertalize.com/r/491818c79fb1873fChaser is the only Slack-native project management platform that helps teams turn messages into tracked tasks, automate follow-ups, and maintain team-wide visibility, without adopting another tool. Now integrated with Claude and other GenAI tools. Learn more at trychaser.com and use code AGILEBRAND for a 3-month free trial (normal trial is 14 days).The most influential minds in software, AI, and engineering leadership will be at WeAreDevelopers World Congress North America, September 23-25 in San Jose. Learn more: https://aglbrnd.co/r/60a7299222a7bcf1Enjoyed the show? Tell us more at and give us a rating so others can find the show at: https://aglbrnd.co/r/faaed112fc9887f3Connect with Greg on LinkedIn: https://www.linkedin.com/in/gregkihlstromDon't miss a thing: get the latest episodes, sign up for our newsletter and more: https://aglbrnd.co/r/35ded3ccfb6716baCheck out The Agile Brand Guide website with articles, insights, and Martechipedia, the wiki for marketing technology: https://www.agilebrandguide.comThe Agile Brand is produced by Missing Link—a Latina-owned strategy-driven, creatively fueled production co-op. From ideation to creation, they craft human connections through intelligent, engaging and informative content. https://www.missinglink.company Hosted on Acast. See acast.com/privacy for more information.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping our industry, starting with a significant regulatory milestone. Vera Therapeutics recently achieved FDA accelerated approval for Trutakna, a groundbreaking treatment for IgA nephropathy. This approval not only provides new hope for patients suffering from this chronic kidney disease but also highlights the innovative approach targeting APRIL and BAFF pathways, crucial in immune system regulation. The drug's accelerated approval is particularly noteworthy as it offers earlier access to promising therapies while further trials solidify its benefits. This positions Vera Therapeutics against industry giants like Novartis and Otsuka in nephrology therapeutics, highlighting the competitive landscape within this sector. The FDA's expedited pathways are increasingly facilitating quicker access to life-saving drugs, aligning regulatory processes with scientific advancements to address unmet medical needs. The spotlight on fusion proteins in tackling autoimmune and renal disorders could signal a broader trend in therapeutic development. In parallel, AstraZeneca has made waves by entering into a major licensing agreement with Sino Biopharmaceutical for their COPD candidate TQC3721. This $1.9 billion deal, with a $200 million upfront payment, exemplifies how global collaborations are becoming pivotal in expanding market reach. By focusing on respiratory diseases, AstraZeneca is strategically positioning itself to enhance treatment options for COPD patients worldwide, reflecting an industry-wide movement towards leveraging regional expertise in drug commercialization. Meanwhile, Evonik's $100 million investment in an Indiana API manufacturing plant marks a strategic effort to bolster domestic production capacities post-pandemic. This investment underscores the rising demand for Contract Development and Manufacturing Organization (CDMO) services, emphasizing supply chain resilience—an increasingly critical factor as biotech firms seek reliable production partners. On the clinical trial front, Satellos Bioscience has reported promising Phase 1 data for SAT-3247, its Duchenne muscular dystrophy candidate. This AAK1 inhibitor demonstrates potential in promoting muscle regeneration, a development that could significantly alter treatment paradigms for this progressive neuromuscular disorder. If further trials confirm these findings, it could revolutionize therapeutic approaches for rare diseases. Financially, Leo Cancer Care's recent $65 million Series D funding is set to advance its upright radiotherapy treatment system. Such innovations aim to improve precision and outcomes in cancer therapy, at the intersection of technology and patient care. Similarly, MeiraGTx's securing of up to $400 million from Oberland Capital underlines ongoing confidence in gene therapies targeting rare ophthalmological conditions. Strategic maneuvers continue to reshape industry landscapes with mergers like that of Caidya and Simbec-Orion forming a global CRO platform aimed at enhancing research capabilities across oncology and rare diseases. Such consolidations reflect broader trends towards operational efficiencies and scaling research capabilities globally. Amidst these developments, quality control remains paramount as evidenced by Amgen's recall of its heart failure drug due to quality concerns. Such challenges reiterate the importance of stringent quality assurance throughout production processes in safeguarding patient safety. Vertex's acquisition of Crinetics for $10 billion marks another strategic expansion into "white space blockbuster opportunities," illustrating how M&A activity is driving companies to bolster pipelines and capitalize on emerging scientific advancements. These developments collectively underscore the dynamic nature of the pharmaceutical and biotech industries as they navigate complex regulatory landscapes, financial recalibrations, and scientific breakthroughs. As companies strive towards more effective and accessible treatments across various therapeutic areas, their ability to adapt to these challenges remains crucial in shaping the future of healthcare delivery. Thank you for tuning into Pharma Daily. Stay informed with us as we continue to bring you the latest insights from the world of pharmaceuticals and biotechnology.Support the show

Erfahre hier mehr über unseren Partner Scalable Capital - dem Broker mit einem der besten YouTube-Kanäle zu Aktien & Investments. Samsung verdoppelt Umsatz, enttäuscht trotzdem. Chip-Aktien fallen. Rivian verkauft Aktien. Vertex kauft Diversifikation. DeepSeek baut eigenen KI-Chip. Proxima Fusion holt 400 Mio. € von Alex Gerko. Nato bestellt bei SAAB. Lockheed & Avio mit Deals. Indien war lang Börsen-Liebling. Jetzt: zu teuer, KI-Problem, Ölabhängigkeit. Christian Röhl erklärt die Lage und wie man Indien im Portfolio spielen kann (z.B. MSCI India, FTSE India, WisdomTree True Emerging Markets (WKN: A41U4P), Suzuki Motors (WKN: 857310)). Diesen Podcast vom 08.07.2026, 3:00 Uhr stellt dir die Podstars GmbH (Noah Leidinger) zur Verfügung. Learn more about your ad choices. Visit megaphone.fm/adchoices

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a series of compelling stories that showcase the dynamic nature of this industry. In a landmark development, Vertex Pharmaceuticals has made headlines with its acquisition of Crinetics Pharmaceuticals for a staggering $10 billion. This move marks Vertex's strategic expansion into the endocrine disease sector, a significant shift from its traditional focus on cystic fibrosis. Crinetics' innovative approach to treating rare endocrine disorders will allow Vertex to address unmet needs in this area, highlighting a broader industry trend where mergers and acquisitions serve as key strategies for adapting to the evolving scientific landscape and patient demands. While Vertex makes bold moves, Kalohexis is preparing for a confidential initial public offering (IPO), focusing on treatments based on the melanocortin system for obesity and cancer cachexia. The melanocortin system is crucial in regulating energy homeostasis and inflammation, making it a promising target for therapeutic interventions. This development underscores the growing interest in peptide-based therapies and innovative scientific approaches to address complex metabolic disorders, further emphasizing the industry's shift towards tackling significant health challenges such as obesity. Clinical trials continue to be at the forefront of medical advancements. Compass Pathways has reported promising Phase III trial results for COMP360, its psilocybin-based therapy for treatment-resistant depression. These findings indicate a potential breakthrough in psychedelic therapy, offering new hope for patients who haven't benefited from existing antidepressant treatments. The exploration of psychedelics in mental health treatment represents a paradigm shift that could introduce novel therapeutic options and significantly impact patient care. Turning to regulatory news, AbbVie's Tepkinly (epcoritamab) has received European Commission approval for treating relapsed or refractory follicular lymphoma. This approval is based on robust Phase III data, underscoring the potential of bispecific antibodies as effective cancer therapies. Similarly, PharmaEssentia's Besremi (ropeginterferon alfa-2b) has obtained Health Canada approval for polycythemia vera treatment, highlighting the continued relevance of protein and interferon therapies in managing myeloproliferative neoplasms. In business development news, Novo Nordisk and Vivani Medical have partnered to develop an ultra-long-acting semaglutide implant for chronic weight management. This collaboration showcases advancements in drug delivery systems aimed at improving patient compliance and therapeutic outcomes. Meanwhile, Boehringer Ingelheim's licensing agreement with Prime Vector Technologies involves harnessing viral vectors for cancer vaccine development, emphasizing ongoing efforts to innovate within oncology. Despite these advancements, challenges persist within the industry. Notably, Bristol Myers Squibb's Krazati (adagrasib) failed its Phase III confirmatory trial in metastatic colorectal cancer with KRAS G12C mutations. This outcome highlights the complexities involved in developing targeted cancer therapies and underscores the need for continued innovation and exploration of combination treatments. The financial landscape also reflects strategic adjustments with Regeneron Pharmaceuticals reporting a $127 million charge impacting its earnings due to an in-process research and development expense. Additionally, Novartis is undergoing organizational restructuring with workforce reductions aimed at cost management within large pharmaceutical enterprises. On another front, China's recent approval of the world's first CAR-T therapy for solid tumors marks a significant leap forward from its traditional success in hematological malignancies. This development highlights the potential for CAR-T therapies to address complex challenges posed by solid tumors and could have profound implications for global cancer treatment paradigms. AstraZeneca's partnership with CSPC Pharmaceutical represents another strategic collaboration aimed at co-developing kidney disease drugs, reflecting Western pharmaceutical companies' efforts to leverage Chinese biotechnological capabilities. As companies navigate these complexities through strategic acquisitions, partnerships, and groundbreaking research, their ability to adapt will be crucial in shaping future patient care and therapeutic landscapes. The pharmaceutical and biotech industries remain at the forefront of scientific advancement, continually seeking solutions to complex medical needs while adapting to an ever-evolving global landscape.Support the show

A surprising deal from Vertex Pharmaceuticals adds to Big Pharma's acquisitive streak as Crinetics folds into the cystic fibrosis drugmaker. Meanwhile, IPOs and venture capital raises trend upward, but mostly for derisked companies. Plus, FDA decisions slow only slightly as the hunt for a permanent leader drags on.

Fredrik snackar shaders med Mårten Rånge. Shaders är små program som skrivs i ett C-liknande språk (GLSL), körs direkt på grafikkort, och ritar grafik (eller skapar ljud) på ens skärm med ofta chockerande lite kod. Mårten ger en introduktion till shaders och vanliga tekniker och begrepp, och det blir mycket grafik, snabb respons, iterativ matematik och programmering med underbart korta återkopplingsloopar och fokus på resultatet. Hur påverkar shadertänk vardagsutvecklandet? Mårten tror att det kanske gett honom mer fokus på att faktiskt lösa problem. Skulle shaders - för rätt personer - kunna vara ett bra första programmeringsspråk? Mot slutet kommer vi också in på att bygga program för DOS och, inte minst, göra program som gör något häftigt och är så små det bara går. 300 bytes till exempel. Tänk så långt RAM skulle räcka om alla program låg i den storleksklassen … Ett stort tack till Cloudnet som sponsrar vår VPS! Har du kommentarer, frågor eller tips? Vi är @kodsnack, @thieta, @krig, och @bjoreman på Mastodon, har en sida på Facebook och epostas på info@kodsnack.se om du vill skriva längre. Vi läser allt som skickas. Gillar du Kodsnack får du hemskt gärna recensera oss i iTunes! Du kan också stödja podden genom att ge oss en kaffe (eller två!) på Ko-fi, eller handla något i vår butik. Länkar Mårten Øredev SQL server COBOL Neo Shader art Shaders TIC-80 - stödjer fler språk än Lua, och har en Webassembly-host så att man kan skriva i vilket språk som helst som kan kompileras till Webassembly Shaders för musik Pestis - crazy på ett bra sätt kring matematik och musik Shadertoy Fragment shader eller pixel shader Vertex shader GLSL - shaderprogrammeringsspråk Kodelife - IDE för shaderprogrammering Posh brolly - annan sida för shaders Fragcoord - ännu fler shaders! Bonzomatic - används för livekodande av shaders Sinusfunktioner Babels bibliotek Ray marching Ray marching-exempel på en sfär på Shadertoy Ray tracing Normal Dot product - eller skalärprodukt på svenska Diffust ljus Distansfält Fraktaler 3D-fraktaler Mandelbulb Clean code Fabrice Neyret Stötta Kodsnack på Ko-fi! ICQ Kodsnack 705 - om signalprocessing och annat Scratch Pacman i Shadertoy Arkanoid Rasterlinjer Mårtens 4 kb-minröjarspel Sointu - ett musikprogram av "en galen finländare" DOS Dosbox Dosbox-X 256-bytes-spel Wake up! 16-bytes-demo i x86-assembler med Matrix-aktig kod och musik (video) COM-program PICO-8 Fantasikonsoll Lua Strudel DJ_Dave och Switch angel Bytebeat Synesthesia Mårtens adventbloggserie om shaders Adventbloggserie för 2025 Bonuslänkar från lyssnare Kolla in shader-livekodnings-tävlingarna på diverse demopartyn, exempelvis finalen från Revision 2024 DOS-like - På tal om låtsasmaskiner och DOS Distansfält implementerade för några 3d-former av Inigo Quilez Distansfält implementerade för några 2d-former av Inigo Quilez Titlar Øredev sade just nej till mig Det jag gör på kvällstid Min primära hobby Crazy på ett bra sätt Jättemycket flops Pixelkoordinat in, färg ut Någon funktion här och där Iterativ matematik Ändlösa rum Resultatet är målsättningen Fyra flyttal Tiden ändrar sig Rakt ut från sfären Riktningen i tre dimensioner Diffust ljus En punkt i rymden Annorlunda patterns Var kom bergen från? Jag hittade 30 bytes till Din shader är optimal Var kommer grafiken från? Det ser ut som magi Tillbaka till rötterna Pseudoslumptal För rätt tonåring Musik, grafik, och spel på fyra kilobyte 240 bytes mindre Det som är minst är bäst Inga abstraktioner att lära sig Hon kodar på scen Andra typer av uniformer

I thoroughly enjoy doing my podcasts. It's the one thing I truly miss from my television news reporting days — interviewing extraordinary people every single day. Through The Bonnell Foundation, I now host a weekly podcast, and honestly, I wish I could do them daily. Not only does it bring me so much joy, but it also gives me the opportunity to share the stories of the incredible people I meet along the way. Kate O'Donnell is one of those people. Kate was inspired by a brother she never met. Her brother Joey died from cystic fibrosis just three months before she was born. CF is a brutal disease, but the community that rises from this tragedy is filled with some of the most inspiring, compassionate, and courageous people you will ever meet. Kate's father, Joe O'Donnell, became one of the cystic fibrosis community's most influential volunteer leaders and fundraisers. Together with his wife Kathy, he founded The Joey Fund in memory of Joey. Today, Kate is helping carry that legacy forward and bringing new energy and passion to the mission. And trust me — by the end of this podcast, you're probably going to want a Joey hat of your own. You can support The Joey Fund here: https://joeyfund.org/donate-1 Kate is smart, fun, energetic, and deeply committed to making a difference in the CF community. I know you'll be inspired by everything she continues to do. Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

הפרק הוקלט במסגרת ⁠אירוע לייב⁠ של מהדורת מוסף. לקבלת עדכונים על האירוע הבא ⁠הצטרפו לקבוצה הסגורה שלנו⁠ ליאור סיימון, שותפה-מנהלת ב​קרן Cyberstarts, ​הגיעה לשיחה פתוחה על מאחורי הקלעים של תעשיית ה​הון-סיכון והטק הישראלי​, בהנחיית ​עמית קרפ ​ (Bessemer​), ברק שוסטר (Battery)​,​ ינאי אורון (Vertex) וגיא קצוביץ' (Fusion). ב​שיחה ​משתפת ​ליאור בגישת ההשקעות ​הייחודית של הקרן ​ואיך היא מלווה את יזמי הפורטפוליו האישי שלה - חברות בשווי מצטבר של כ-15 מיליארד דולר​ - ומסבירה מדוע הליווי האישי והנפשי של היזמים חשוב לא פחות מהצד העסקי. ב​נוסף, היא משתפת בפלייבוק של יזמי הקרן להצלחה, ההתמודדות עם בניית ​חברה חדשה בשוק תחרותי, והתכונה האחת שמשותפת לכל היזמים המצליחים.(00:00:00) היכרות עם ליאור וההצלחה של סייברסטארטס (00:02:45) תזת ההשקעות ושיטת העבודה של הקרן (00:07:16) האם יזמים באמת צריכים את העזרה של הקרן? (00:09:23) הבדידות בצמרת והאתגרים האישיים של מנכ"לים (00:14:57) הכוח בלהיות קרן נישתית וממוקדת (00:16:23) חברות שלוקח להן זמן לפרוץ ויצירת קטגוריה חדשה (00:20:11) צמיחה מהירה והתמודדות בשוק תחרותי (00:22:06) התכונה המשותפת לכל היזמים המצליחים

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of remarkable advancements and strategic maneuvers that are shaping the future of drug development and patient care. Starting with Roche's breakthrough in oncology, their small molecule inhibitor, Divarasib, has shown promising results in a Phase 3 trial for patients with KRAS G12C-mutated non-small cell lung cancer. This trial demonstrated superior efficacy over competitors like Amgen's Lumakras and Bristol-Myers Squibb's Krazati. Historically, KRAS mutations have been difficult to target, but Divarasib's success underscores the potential of precision medicine in oncology. These findings could lead to more effective treatment options for NSCLC patients, showcasing how targeted therapies are revolutionizing cancer treatment by focusing on specific genetic mutations. In regulatory news, Vertex Pharmaceuticals has made significant strides with Casgevy (exagamglogene autotemcel), a gene therapy that now includes pediatric patients with sickle cell disease and transfusion-dependent beta thalassemia in its FDA-approved label. This marks a pivotal moment for gene therapy applications in blood disorders. Utilizing CRISPR technology, Vertex offers potentially curative solutions for debilitating conditions, signaling a new era where genetic disorders can be addressed at their root cause. Similarly, Novartis has gained European Commission approval for Itvisma to treat 5q spinal muscular atrophy in patients aged two years and older, further cementing gene therapies' role in mainstream medical practice. Strategic partnerships remain essential in driving innovation. Takeda's collaboration with Insilico Medicine on AI-driven drug discovery is a case in point. The $600 million partnership highlights the growing reliance on AI and machine learning to expedite therapeutic development processes. Platforms like Pharma.AI are being leveraged to identify novel drug candidates more efficiently. Additionally, AstraZeneca's alliance with CSPC Pharmaceutical Group to develop siRNA-based therapies for kidney diseases reflects the burgeoning interest in RNA therapeutics as these technologies open new avenues to address complex diseases. On the financial front, BridgeBio's ability to attract $1 billion in convertible preferred equity from Sixth Street and Healthcare Royalty underscores investor confidence in rare disease therapeutics. This funding will bolster its pipeline targeting cardiovascular and rare conditions, emphasizing the profitable potential found within niche markets of the pharmaceutical landscape. Manufacturing is also seeing expansion as Lonza deepens its partnership with an unnamed U.S. drugmaker to enhance biologics programs. Anticipated investments reaching into multi-billion Swiss Francs underscore the critical importance of robust manufacturing infrastructure to meet growing demands for biologics and antibody-drug conjugates. Clinical trials continue to yield promising results. Can-Fite Biopharma's Phase 2a trial for Namodenoson in treating advanced pancreatic ductal adenocarcinoma has shown promising survival data when combined with therapies targeting Wnt/β-catenin signaling pathways. At the same time, Otsuka's Phase 3 data for Voyxact (sibeprenlimab-szsi) demonstrated improved kidney function in patients with immunoglobulin A nephropathy, bolstering traditional FDA approval pathways. On the acquisitions front, GNI Group's acquisition of Ayumi Pharmaceutical for approximately JPY 44.8 billion highlights strategic moves to enhance global biopharma operations focusing on pain management solutions. Yet not all news is positive; Sanofi's Genzyme Ireland unit received an FDA warning letter regarding manufacturing violations related to Altuviiio production, pointing to ongoing regulatory challenges within production practices. Moving on to geopolitical considerations, recent congressional letters to major pharmaceutical CEOs have raised concerns about clinical trials conducted within China due to national security concerns. This tension illustrates the delicate balance between leveraging China's economic potential and safeguarding US interests—a critical issue as international collaborations continue to expand. Meanwhile, AstraZeneca's ongoing collaborations with CSPC Pharmaceutical Group further signify strategic bets on China's capabilities despite geopolitical tensions. Their joint efforts focus on kidney disease treatments while adding to existing agreements addressing obesity and chronic diseases. The FDA remains pivotal as key decisions anticipated this quarter could significantly influence investment strategies and research priorities. This includes revisiting applications previously delayed or rejected—decisions that could reshape industry dynamics. In conclusion, this dynamic landscape is marked by significant scientific breakthroughs and complex global interactions guiding pharmaceutical and biotech sectors toward a transformative era. Gene therapy advancements underscore progress in personalized medicine while geopolitical factors continue influencing strategic industry decisions. As regulatory bodies evolve their approaches alongside increasingly international partnerships, these developments collectively herald profound implications for drug development and patient care globally.Support the show

Jon Gay and I had a great time recording this podcast because we not only talked about podcasting, but also reflected on our years in the broadcast business and what people should know before starting a podcast of their own. There's a lot of laughter, behind-the-scenes stories, and practical insight for anyone curious about the world of audio storytelling. Jon and I go way back to our radio days. We worked at different stations in the same building, crossing paths in a fast-paced world built on deadlines, storytelling, and finding the right words at the right moment. Radio teaches you quickly how to think on your feet, write with purpose, deliver information clearly, and connect with people through your voice. What's interesting is that neither of us spent much time trying to “sound like radio people.” We focused on being authentic, credible, and conversational. The voice came naturally because the storytelling mattered more than the performance. For me, podcasting became a natural extension of the work I do with my Foundation. It gave me a platform to continue having meaningful conversations, telling important stories, and creating a space where people feel comfortable enough to share their experiences honestly. That's one reason I was thrilled to eventually hire Jon as my podcast editor. I already knew his professionalism, creativity, and work ethic from our radio days, and he understood the heart behind what I was trying to create. Jon has a real talent for shaping conversations into stories that people genuinely connect with. In this episode, we talk about the evolution from radio to podcasting, the art of authentic storytelling, and why genuine connection matters more than ever in today's media landscape. And finally, Jon, it seems like everyone wants to start a podcast these days. I can't tell you how many people ask me where to begin, and honestly, I don't always have the time to walk everyone through it. So when someone comes to you and says, “I want to start a podcast,” what's the very first thing you tell them? If you want to talk with Jon you can contact him here: jag@jagpodcastproductions.com Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Send us Fan MailFor decades, scientists have searched for better cancer drugs. But what if the biggest challenge isn't discovering the drug - it's getting it to the tumor? My guest today is developing programmable viruses designed to travel throughout the body, selectively amplify inside metastatic lesions, and transform tumors into factories for their own destruction.Dr. Eric Poma, Ph.D. is Chief Executive Officer of Calidi Biotherapeutics ( https://www.calidibio.com/ ), a biotechnology company developing targeted genetic medicines designed to deliver therapeutic payloads directly to tumors throughout the body.Dr. Poma brings more than three decades of experience across biotechnology, oncology drug development, business development, and capital markets. Prior to joining Calidi in 2025, he served as CEO of Molecular Templates, where he helped raise more than $250 million in equity financing and secured strategic partnerships with companies including Takeda, Vertex, and Bristol Myers Squibb.Earlier in his career, Dr. Poma held leadership roles at ImClone Systems during the rise of targeted cancer therapies, served as Vice President of Business Development at Innovive Pharmaceuticals, and worked as a healthcare and biotechnology analyst. He holds a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill and an MBA from NYU's Stern School of Business.Today we will discuss one of the most difficult challenges in oncology - how to successfully deliver powerful therapies to metastatic tumors throughout the body - and how Calidi's RedTail platform aims to use engineered oncolytic viruses as targeted delivery vehicles capable of reaching cancer cells, modifying the tumor microenvironment, and potentially enabling a new generation of genetic medicines.#CancerResearch #Oncology #Immunotherapy #GeneTherapy #Biotechnology #CancerTreatment #PrecisionMedicine #OncolyticVirus #CancerScience #BiotechInnovation #MetastaticCancer #IL15 #VacciniaVirus #GeneticMedicine #SyntheticBiology #TumorMicroenvironment #FutureOfMedicine #DrugDelivery #Biopharma #EricPoma #CalidiBiotherapeutics #CancerBreakthrough #MedicalInnovation #LifeSciences #ProgressPotentialPossibilitiesSupport the show

Lower C-section rates, faster deliveries, and less physician burnout: could the OB hospitalist model deliver all three? In this episode of BackTable Women's Health, host Dr. Nicole Faulkner interviews Dr. Maliha Sayla, a board-certified OBGYN and medical director of labor and delivery at Northwestern Medicine Delnor Hospital, to explore how the OB hospitalist model is reshaping care for physicians, patients, and healthcare systems. --- Get the BackTable apphttps://www.backtable.com/app --- Timestamps 00:00 - Introduction 03:27 - Why Hospitalists Matter05:33 - How Their Model Works07:15 - Managing Pushback10:18 - Measuring Better Outcomes15:58 - Drills and Emergencies19:50 - Staffing and Transition24:33 - ROI and OB-ED26:33 - Residents and Teaching30:52 - Future Flexible OB Careers34:14 - Patient Acceptance of Model36:47 - Collaboration and Lifestyle Balance40:00 - Conclusion --- More about this episode Dr. Sayla shares her journey from traditional private practice to full-time OB hospitalist work, explaining how this model reduces physician burnout by making labor and delivery a dedicated role rather than one juggled alongside clinic visits, surgeries, and administrative responsibilities. She details her institution's staffing structure, where hospitalists provide continuous labor and delivery coverage, allowing generalist OBGYNs to focus on outpatient care. Dr. Sayla highlights the benefits of having dedicated physicians available for bedside counseling, fetal monitoring, and real-time decision-making. The episode explores improvements in communication, collaboration, and patient outcomes, including lower NTSV (Nulliparous, Term, Singleton, Vertex) cesarean rates and shorter induction-to-delivery times after adopting the hospitalist model. Additionally, she discusses the hospitalist role in obstetric emergency preparedness and interdisciplinary collaboration, patient perspectives, and the potential of hospitalist programs to address OBGYN workforce shortages. --- BackTable Women's Health is the go-to podcast for gynecologists, gynecologic surgeons, and other healthcare professionals focused on women's health. Download the free BackTable app to get early access to new episodes, cases, and courses curated by physicians in your specialty. ► https://www.backtable.com/app

"Many people have their own thing that lights them on fire, for me, it's running" say Katie O'Grady.  CF modulator drugs changes are a game changer for people living with cystic fibrosis. Katie O'Grady's story is a powerful reflection of how dramatically life with cystic fibrosis has changed in the era of CF modulators, and what becomes possible when hope replaces survival mode. A runner, speaker, and cystic fibrosis advocate in Boston, Katie redefined what it means to live with CF. Katie inspires us by talked about her shift in mindset and how it changed everything: she stopped thinking of herself as “a CF patient who runs” and began identifying as “a runner who happens to have CF.” That subtle but profound change transformed not only the way she trained, but the way she cared for herself, viewed her future, and moved through the world. For much of her life, Katie lived the reality many people with CF know too well — moving from infection to infection, never fully certain what the next year, or even the next season, might bring. At 18, she battled a devastating case of pneumonia that forced her to confront the fragility of her health. But in 2019, everything changed with the arrival of Trikafta. For the first time, Katie could imagine a future without immediately attaching fear or limitations to it. She speaks candidly about what it means to rebuild trust in your body after years of illness, and how running became far more than exercise. It became freedom, therapy, identity, and proof that her diagnosis did not get to define the boundaries of her life. Katie opens up about taking the longest break from running she'd ever experienced, wondering if she would ever return, and discovering that what she missed most wasn't competition — it was the clarity, peace, and sense of self she found while moving. To watch on YouTube: https://www.youtube.com/watch?v=zzdQraUAPfc Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Jay Gunkelman goes in BLIND on a 10-year-old's EEG — no diagnosis, no story. What he finds isn't a broken brain: it's gross over-arousal with FAST alpha near 12 Hz, beta spindling up at 32 Hz that a database stopping at 30 would never see, and a left-side sympathetic source pointing at the insula. The likely complaint? Anxiety — maybe labeled OCD, maybe pushed toward an SSRI that would make this brain worse, not better. Jay lays out the actual fix: the Scott protocol's pre-treatment FIRST (calm the sympathetic trigger and slow content), THEN slow-alpha and alpha-theta training to drop the arousal. Read the brain, and the trajectory of a whole life changes. Plus: Joshua Moore previews his first QEEG-phenotypes workshop.

“Take in your final breath before your first new one.”  Those were the words Jillian heard before her double lung transplant—words that would mark the end of one life chapter and the beginning of another. Jillian is 34 years old, living with cystic fibrosis, and a double lung transplant recipient. Her story is one of resilience, loss, hope, and purpose. From being diagnosed at birth to navigating adulthood, Jillian has faced more than most, but she continues to show up for her life and for others in the cystic fibrosis community. Jillian shares what it was like growing up with CF, supported by family and shaped by early connections within the community. She reflects on how advocates like Emily Schaller and the Rock CF Foundation influenced her outlook and helped her feel less alone. We also talk about her college years, what it meant to pursue independence while managing a complex disease, and how life shifted as her health declined into end-stage lung failure. Jillian walks us through the transplant process, not just medically, but emotionally—the fear, the uncertainty, and the strength it takes to keep going. One of the most profound parts of Jillian's story is the loss of her twin brother. She opens up about that grief and how it continues to shape her perspective, her resilience, and her compassion for others. Throughout it all, Jillian emphasizes the importance of support systems and mental health—especially during the transplant journey. No one goes through something like this alone, and her story is a reminder of how critical connection and care truly are. Today, Jillian looks toward the future with hope. She shares her dreams of building a family, continuing her advocacy work, and expanding the impact of the nonprofit she founded, Jillian's Jay Walkers Organization. Her story is not just about survival—it's about living with intention, honoring loss, and creating something meaningful from it all.

Today on this edition of the Zone 103 Math Shorts that is Vertex Quadratic FunctionsRecorded 4/11/2026

In this live client reading, I do a 90-Day Astrology Roadmap reading for Dino. He's anticipating a major shift in his job responsibilities and getting ready to move in with his girlfriend. He's also about to have transiting Uranus square his natal Sun and Venus, so I tell him how to make the best use of one of the most potent transits of his lifetime. Because it isn't just Uranus: Neptune and Pluto also aspect his Sun and Venus at the same time! RESOURCES New service: 90-Day Astrology Roadmap Reading Dino's 90-Day Astrology Roadmap report Dino's event list Dino's natal chart 2:56 - Quick natal chart overview 6:07 - 90-day report overview 7:24 - 90-day event list 8:09 - The Big Picture 11:32 - Relocation and relationship 12:07 - Key Timing Window 1, June 7-13 - Healing Relationship Patterns and Choosing Your Path 12:43 - Lunar nodes discussion 17:58 - T-Saturn conjunct Chiron and Eris in 7th house 21:35 -  Key Timing Window 2, June 14-25 - A Major Turning Point in Purpose, Identity, and Public Life 21:44 - Gemini New Moon aspecting the angles, Pluto, and Vertex 25:36 - Outer planet aspects to Mercury (Midheaven ruler) 27:45 -  Past career effects of outer planets aspecting Mercury 31:59 - Key Timing Window 3, June 26-July 10 - Reviewing Your Direction While Refining Your Message 35:02 - Key Timing Window 4, July 11-25 - Breaking Free From Old Identities and Embracing Authenticity 38:03 - T-Uranus square Sun and Venus 56:35 - All three outer planets aspecting Sun and Venus 1:02:16 - Highlighted Themes 1:07:17 - Most Favorable Windows 1:09:22 - Most Challenging Windows 1:11:29 - Bottom Line Summary Learn my invocations for healing and awakening in my FREE life-transforming video: Instant Divine Assistance: Your Free Guide to Fast and Easy Awakening, Healing, and More. Let my Awakening Plus membership help you awaken, heal, connect, and thrive! "This Week in Astrology" Free Session Entry. (2 chances each month to win a free session with me!) My forecasts in writing. My services: Astrology+, Energy Healing & Spiritual Guidance, life coaching, Deep Dive Trauma Healing, and more.  Apply to have me do a free reading for you on "This Week in Astrology." Support my work with your tax-deductible donation. Watch the video. May the stars light your way, Benjamin

What does good care actually look like for adults living with sickle cell disease?In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter focuses on navigating treatment options and disease modifiers. Dr. Kanter breaks down the most prominent medications and therapies available today, including hydroxyurea, crizanlizumab, L-glutamine, and blood transfusions, explaining how patients and providers can work together to personalize care and find the best treatment path.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the ⁠National Alliance of Sickle Cell Centers⁠ (NASCC).This episode is part of Sickle Cell 101's Care and Treatment 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Care and Treatment 101 sponsors: ⁠Vertex⁠, ⁠Chiesi⁠, ⁠Pfizer⁠, and ⁠Medunik⁠.

Chrisy and Dr. Kingzett, two women I met when we were all trying to raise our rare voices a little louder. Christine “Chrisy” Klavitter and Dr. Kristen Kingzett are both rare disease advocates, but more importantly, they are people living this reality every single day. Chrisy lives with Stiff Person Syndrome and Myositis. Kristen is an Internal Medicine physician and an ultra-rare cancer survivor. Together, we talk about what life with rare disease actually looks like—beyond the statistics. From delayed diagnoses (which can take years, even decades) to the emotional and physical toll of navigating a fragmented healthcare system, this conversation is honest, eye-opening, and necessary. More than 30 million people in the U.S. are living with a rare disease—defined as affecting fewer than 200,000 people. Yet despite those numbers, patients are still too often misunderstood, misdiagnosed, or left to navigate care on their own. Chrisy and Kristen share what an average day can look like, the full-time job of managing health (or caring for someone who is), and what happens when patients have to push back—even redirect—the so-called experts. We also dig into the bigger questions: Why does diagnosis still take so long—and how do we fix it? What do providers, institutions, and policymakers still not understand? What do you say to someone who believes “there's nothing I can do”? And where are we actually seeing progress in healthcare? What stands out most is this: patients are not passive participants in their care—they are often the ones holding it all together. About my guests: Dr. Kristen Kingzett is an Internal Medicine physician, educator, and advocate who brings both professional expertise and lived experience, including Juvenile Idiopathic Arthritis, Common Variable Immune Deficiency, and an ultra-rare cancer. She serves on Michigan's Rare Disease Advisory Council and Legislative Disability Caucus. Chrisy Klavitter is a healthcare policy and patient advocate, biologist, and recreation therapist. Living with Stiff Person Syndrome and Myositis, she works to bridge communication gaps between patients, providers, researchers, and policymakers to improve care for complex conditions. The takeaway? Rare disease may be defined by numbers, but its impact is anything but small. And if we build a healthcare system that works for rare disease patients, we build one that works better for everyone. Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

“Behind every breakthrough are countless failures no one ever sees—but that's exactly what makes progress possible.” Dr. Thomas Kaiser. When I have scientists on the podcast: they're some of the coolest, smartest, funniest people, and they're always willing (and excited) to explain what they do in ways you can actually understand. Dr. Tom Kaiser is no exception. He lives and works in Durham, North Carolina, and brings together an impressive mix of scientist, physician, and entrepreneur. His work focuses on designing better medicines using cutting-edge technology. He began his career at Emory University in Dennis Liotta's lab, working on antiviral drug discovery, and later helped pioneer early machine learning approaches in drug design. His research spans RSV, cancer, and neurodegenerative diseases, and he went on to earn his medical degree from the University of Oxford. Tom is now the co-founder and Chief Scientific Officer of Avicenna Biosciences, where he's leading the development of innovative therapies aimed at improving and saving lives. And my favorite detail from his bio? He ends it by mentioning the love of his life, his wife. I'll be honest, when I first met him, I told Dr. Kaiser he seemed like someone who must have been in a movie. He's just that cool. His Company: Dr. Thomas Kaiser shares the story behind his company's name, Ibn Sina, also known as Avicenna a true Renaissance figure of the Islamic Golden Age. A physician, philosopher, and scientist, Ibn Sina embodied the kind of multidisciplinary thinking that still drives innovation today. It's a powerful reminder that the roots of modern medicine, and the spirit of discovery stretch back centuries. The Part We Don't Talk About Enough Science is not a straight line. Not even close. Experiments fail. Clinical trials don't work. Hypotheses fall apart after years of effort. Funding can disappear. Progress can stall in ways that are frustrating and sometimes heartbreaking especially when patients are waiting. Dr. Kaiser speaks about this with a clarity and calm that really stayed with me. Because the truth is: scientists have to keep going anyway. They carry the weight of those disappointments and start again. They adjust, rethink, rebuild, and try again. Over and over. And that persistence? That's where breakthroughs come from. From the outside, it's easy to celebrate the wins ... the new drug, the successful trial, the headlines. But behind every one of those moments are countless failures no one ever sees. For families like ours, waiting, hoping, advocating it matters to understand that this difficult process is also what makes progress possible. Living the Dream What if you actually got to live the dream you had as a kid? In this conversation, Dr. Thomas Kaiser shares something surprisingly personal: he feels lucky to be doing exactly what he dreamed of as a child. That early curiosity grew into a career designing new medicines and pushing the boundaries of science. From imagination to impact, his journey is a reminder that sometimes those childhood passions really can shape the future. Go to Dr. Kaisers website:  https://www.avicenna-bio.com Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

What does good care actually look like for adults living with sickle cell disease? In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter breaks it down. She covers establishing a medical home, working with a sickle cell specialist, navigating the Emergency Department, and building an Individualized Care Plan that works for you.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the National Alliance of Sickle Cell Centers (NASCC).This episode is part of Sickle Cell 101's Care and Treatment 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Care and Treatment 101 sponsors: Vertex, Chiesi, Pfizer, and Medunik.

What does good care actually look like for adults living with sickle cell disease? In this episode of our What Good Care Looks Like for Adults with Sickle Cell series, lifespan sickle cell expert Dr. Julie Kanter focuses on two pillars of quality sickle cell care: working with the right specialists and understanding the lab work that guides your treatment.Dr. Julie Kanter is the Co-Director of the Lifespan Comprehensive Sickle Cell Center at the University of Alabama at Birmingham and President of the National Alliance of Sickle Cell Centers (NASCC).This episode is part of Sickle Cell 101's Care and Treatment 101 Educational Initiative, a community resource dedicated to making care information accessible and actionable for the sickle cell community.Thank you to our Care and Treatment 101 sponsors: Vertex, Chiesi, Pfizer, and Medunik.

Living Fully with CF: Christopher Cornejo's Journey from Diagnosis to Avatar This fast-moving and deeply engaging conversation features Christopher Cornejo, who brings a fresh and powerful voice to the cystic fibrosis community. Diagnosed with CF as an adult just three years ago, Christopher has quickly become an advocate, sharing his story on stage at a UCLA CF symposium and being honored by the Cystic Fibrosis Foundation as one of Southern California's Finest. What makes Christopher's story especially compelling is his perspective, shaped not only by his diagnosis, but by his career in film, including his work as a technical director on Avatar 2 and 3. In this heartfelt interview, Christopher opens up about his late diagnosis, navigating medical challenges, and how openness, community, and resilience have shaped his journey. We talk about his later diagnosis, balancing his health and his demanding film career, the importance of community and support along with his mental health and resilience.    Like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredNew: Shop our merchandise! https://thebonnellfoundation.org/product-shop/Thanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

A mother, advocate and one woman's global fight for access. Beth Vanstone is working to ensure rare disease patients don't have to wait for the treatments they need to survive. Sometimes the most powerful friendships begin in the most unexpected places.  Beth Vanstone and I first connected on social media. At the time, we were simply two moms navigating the complicated, emotional, and relentless world of cystic fibrosis. But eventually the online messages turned into something more meaningful. Then, Beth attended one of The Bonnell Foundation's Gala events. That's when we finally met in person.  And from that moment on, we became dear friends.  It's proof that social media, when used for connection and purpose, can build incredible relationships. But what inspires me most about Beth isn't just our friendship. It's her relentless determination. Beth is the mother of Madi, who was diagnosed with cystic fibrosis at just eight months old. Suddenly Beth was navigating a healthcare system, researching treatments, learning medical language, and fighting for her daughter's future. Beth didn't stop there. Instead of focusing only on her own family, she chose to fight for every family. Today, Beth is a powerful advocate in Canada and a member of the Ontario Rare Action Group, where she works to improve access to life-saving therapies for people living with rare diseases like Cystic Fibrosis. And the reality she's fighting against is one many people don't understand. Most healthcare systems, not just in Canada but around the world were built to treat common diseases. They weren't designed for rare conditions that affect smaller populations. Because of that, patients with rare diseases often face enormous barriers: long approval timelines, delayed access to medications, and exhausting advocacy battles just to receive treatments that already exist. In some cases, patients wait months — even years — for medications that could dramatically improve or extend their lives. Beth is working to change that. Through her advocacy, she's pushing for reforms that could make a real difference for patients across Canada and beyond: • Faster access to innovative therapies • Improved newborn screening programs • Better diagnostic pathways • Centers of excellence for rare diseases • Removing financial barriers like deductibles that prevent families from accessing public programs And she's also raising an important global conversation. Here in the United States, lawmakers have debated policies like the Most Favored Nation Model, which look to international drug pricing systems like those in Canada and Europe as a model. But Beth reminds us that every system has challenges, and for rare disease patients, those challenges can be life-changing. Because when access to medication is delayed… Access is denied. And that's why advocacy across borders matters. She's not just advocating for her daughter. She's advocating for every patient still waiting for their breakthrough. And today, we're talking about what needs to change and how all of us can help make it happen. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Building software inside a frac and wireline giant is a different beast than doing it at a startup. Ben Dickinson and Raleigh Bumpers from NexTier Completion Solutions get into life under the Patterson UTI umbrella, the EOS platform, the Vertex automated pump control system, the shift from diesel to natural gas powered fleets, agentic AI in the field, and why the world genuinely stops if oil and gas stops. Plus Pittsburgh shale stories and a Colorado School of Mines reality check.Click here to watch a video of this episode.Join the conversation shaping the future of energy.Collide is the community where oil & gas professionals connect, share insights, and solve real-world problems together. No noise. No fluff. Just the discussions that move our industry forward.Apply today at collide.ioClick here to view the episode transcript. 0:00 The NexTier 60-second pitch2:00 Why integrating every service on location wins4:30 Ben's path from Pittsburgh to wireline to digital11:15 Raleigh's jump from computer science to the Eagle Ford17:00 If oil and gas stops, the world stops19:30 Pittsburgh, the shale boom, and incoming data centers21:30 Completions 10123:30 The EOS platform and Vertex automated pump control27:00 Earning trust from veteran hands on new software32:00 Generative AI versus agentic AI in the field34:00 Diesel, natural gas, and electric frac fleets41:30 Colorado School of Mines and the next generation44:00 The road to a fully autonomous well site46:30 The 80 percent AI failure rule debatehttps://twitter.com/collide_aihttps://www.tiktok.com/@collide.iohttps://www.facebook.com/collide.iohttps://www.instagram.com/collide.iohttps://www.youtube.com/@collide_iohttps://bsky.app/profile/collide-ai.bsky.socialhttps://www.linkedin.com/company/collideai

Bridging Two Countries, One Mission: Cesar and Nora Hernandez Fight for Spanish-Speaking CF Families “When Alex was diagnosed, we felt fear and responsibility. If we had access to information in Spanish, other families should too. No one should feel lost because of language.” Nora Hernandez From Mexico to Mission: How Cesar and Nora Hernandez Are Closing the CF Information Gap for Hispanic Families. “I came to this country to build a better future for my family. I never imagined that future would include fighting for awareness about cystic fibrosis, but now it's part of our mission.” Cesar Hernandez Cesar and Nora Hernandez were both born in Mexico, where accurate and accessible information about cystic fibrosis has not always been readily available. While progress is being made, with more experienced physicians and improving CF care, there is still significant work to do. In the United States, members of the Hispanic community are often underdiagnosed or diagnosed later than others. That gap in awareness and access is one of the reasons The Bonnell Foundation launched its CF Familia page, offering reliable information in both English and Spanish to help families navigate the complexities of cystic fibrosis. Cesar and Nora serve as ambassadors for this effort, creating videos that provide education, updates, and reassurance to Spanish-speaking families. Cesar also serves as a board member of The Bonnell Foundation, and we are deeply grateful for his leadership and heart for this community. Cesar originally came to the United States to build a better life and financially support his family in Mexico. After meeting Nora, he made the decision to stay and make the U.S. his permanent home. Together, they are raising two children, Scarlett and Alex, who was diagnosed with cystic fibrosis. Their story is one of resilience, faith, cultural pride, and advocacy. Transcript is also available on this podcast.     Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

On this week's episode, Josh Schimmer, Paul Matteis, Eric Schmidt, Yaron Werber, and special guest STAT's Allison DeAngelis open with what they describe as “a bananas week for biotech,” highlighting strong substantial secondary offerings, including Cytokinetics and Avalo Therapeutics. The conversation then turns to M&A, with multiple new deals announced in Q1 and continued activity this week, including UCB's acquisition of Candid Therapeutics for up to $2.2B, Angelini's $4.1B purchase of Catalyst Pharmaceuticals, and Bayer's acquisition of Perfuse for up to $2.45B. The group also reflects on what feels like the year of developmental-stage biotech, highlighting investor focus on companies with pipeline events such as Vertex and Biogen, while commercial-stage companies have lagged. In regulatory news, the co-hosts discuss Sanofi's decision to withdraw diabetes drug, teplizumab, from the Commissioner's National Priority Review program, broader concerns about shifting goalposts and political influence, and contradicting outcomes including Replimune's rejection versus Atara's reversal. On the data front, the hosts discuss Cytokinetics' Phase 3 results and subsequent $650M raise, as well as encouraging autoimmune data from Artiva Biotherapeutics. They also overview neurofilament as a biomarker following Clene's data, and J&J's decision to advance its DUET program despite failing to meet its primary endpoint in IBD. *This episode aired on May 8, 2026.

Finding Strength After Loss: A Conversation with Margarete Cassalina I first met Margarete Cassalina when we were hosted for dinner by Bob Emmelkamp at the North American Cystic Fibrosis Conference (NACFC). We connected immediately. There was an ease to our conversation, a shared understanding that doesn't require much explanation in the cystic fibrosis community. And I have to say, her husband Marc is just as wonderful. They are the kind of people you feel grateful to know. I'm so glad we are in this CF life together. Margarete is an author, speaker, and longtime advocate and fundraiser for the Cystic Fibrosis Foundation. But long before the stages, the fundraising events, and the national advocacy, she was a mom navigating the daily realities of cystic fibrosis. In 2006, her 13-year-old daughter, Jena, died from CF. In the depths of unimaginable grief, Margarete made a powerful decision: she would honor Jena's life not only with love, but with action. Since then, she has dedicated herself to storytelling, advocacy, fundraising, and speaking across the country about resilience, motherhood, loss, and the urgent need for continued research. Margarete's son, Eric, also lives with CF, and in this episode you'll hear more about how he's doing and what life looks like for their family today. This dynamic, incredible woman will inspire you. Her story is not only about loss it's about purpose. It's about choosing to move forward when standing still might feel easier. And it's about doing great things in the name of someone you love. To find her books go to Amazon.     Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Sponsored by Chargebee, subscription and revenue management → check out their startup offer: https://www.chargebee.com/startups Jeff Gibson, Founder of Kintsugi https://www.linkedin.com/in/jeffgibsonsf/?utm_source=chatgpt.com - Kintsugi, founded by Jeff Gibson, provides an AI-driven platform that automates global indirect tax compliance (VAT, GST, sales tax, etc.) for internet businesses, handling tax calculation, collection, and remittance. - The company targets SMBs and mid-market companies selling online, offering a simple, automated solution to a complex, high-risk compliance problem, resulting in high customer retention and low churn. - Kintsugi's founding insight came from the realization that businesses were paying more for tax compliance than for billing solutions, and that the market was underserved, especially for SMBs and mid-market companies. - The company raised a $2M pre-seed round in September 2023 from angels, followed by an $18M Series A led by Vertex.  - Jeff emphasizes the importance of founder conviction, qualifying investors for deep understanding of the problem, and building trust with customers in a “boring but essential” fintech space.

Education, connection, and community are at the heart  of our CF community. On Saturday, April 18th from 11:00 a.m. to 1:30 p.m. we gathered at the Next Step Gallery in Ferndale. Set in a bright gallery space surrounded by art, the event offered a welcoming environment for meaningful conversation, learning, and connection. It was pure joy with the smell of great food in the air. Food from my sister in laws restaurant, Bangkok Cuisine (in Royal Oak) filled the air, it smelled amazing and filled the air. Education Day is more than a traditional event. It's an opportunity for people living with cystic fibrosis, parents, caregivers, healthcare professionals, and advocates to gather in one space to share experiences and support one another. A highlight of the afternoon was our “live” podcast recording, offering attendees a chance to hear authentic conversations about life with cystic fibrosis, advocacy, and the challenges and hopes shaping the community today. We all talked about education, advocacy, and what lies ahead for the CF community. The relaxed setting allowed people to connect not just through information, but through shared experiences. Events like Education Day help strengthen the bonds within the CF community by reminding everyone that they are not alone in their journey. Whether you are living with CF, raising a child with the disease, working in healthcare, or supporting someone you love, this gathering is meant to inform, inspire, and bring people together. Every story matters. Every voice matters. And every person who attends becomes part of the conversation. To watch the the premiere of our Embracing Egypt podcast enjoy it here:  https://youtu.be/SlMscQ6Spjg   Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

In this episode, Paula introduces one of the most overlooked—and powerful—points in astrology: the Vertex. Often called the “point of fate,” the Vertex reveals what you're naturally aligned to attract in this lifetime, not what you have to chase. She breaks down where to find it in your chart, why the sign matters more than the house, and how it differs from the more conscious, action-driven Ascendant. Through real-life examples and personal stories, Paula explains how the Vertex shows up as unexpected opportunities, chance encounters, and life-altering moments that feel too perfectly timed to be random. From attracting relationships and resources to aligning with your life's path, this episode will help you recognize the patterns that have already been unfolding for you—and show you how awareness gives you leverage, not control. If you've ever felt like certain moments in your life were “meant to happen,” this episode will help you understand why.

“Being a CF aunt has shaped so much of my life. Now I get the opportunity to turn that love and connection into helping even more people at Breathe Strong CF."  Julie Dunn Eichenberg didn't just find the cystic fibrosis community, she's been part of it for more than 30 years as a proud CF aunt. That personal connection is what makes this next chapter so meaningful. Julie recently stepped into the role of Executive Director at BreatheStrong CF, where the focus is on helping people with cystic fibrosis live stronger, healthier lives through exercise, education, and empowerment. And while she brings decades of experience in leadership, fundraising, and relationship-building, she's honest about getting used to the role. She's learning. Listening. Figuring out the day-to-day. And really taking the time to understand how she can best serve the community in this new position. Before this, Julie spent 20 years at Turner Broadcasting System (now part of Warner Bros. Discovery), and later held leadership roles at Florida State University and Fan Data Insights. But no matter where her career took her, the CF community was always part of her life. She's also been deeply involved with the Cystic Fibrosis Foundation, serving as Chair of the Georgia Chapter and contributing at the national level. We talk about what it feels like to step into a leadership role that's so personal. The excitement, the pressure, and the responsibility that comes with it. Julie shares what she's learning, what's surprised her, and why her connection as a CF aunt continues to guide every decision she makes. Because for Julie, this isn't just a job,  it's personal. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

This Biotech CEO Created The RedTail Platform To Fight Cancer. Guest:Eric PomaCEO of Calidi Bio CLDI Company Name:Calidi BiotherapeuticsWebsite: https://www.calidibio.com/Ticker: NYSE: CLDIEric's Bio:Eric Poma, Ph.D. has served as Chief Executive Officer and board director of Calidi since April 2025 and brings more than 30 years of experience in the biopharmaceutical industry, with a strong record of capital fundraising, big pharma collaboration agreements, and clinical program development.Prior to joining Calidi, Dr. Poma served as CEO of Molecular Templates (NASDAQ: MTEM), a clinical-stage biotech focused on the development of a novel class of therapeutic agents with unique biology in oncology. At Molecular Templates he raised over $250 million in equity financing and secured over $150 million in strategic capital through agreements with Takeda, Vertex and BMS. He previously served as Vice President, Business Development of Innovive Pharmaceuticals. Prior to that he held various senior level positions at Imclone Systems, Inc., primarily in business development. Earlier, Dr. Poma served as a Healthcare & Biotechnology Analyst with the healthcare fund Eagle Growth Investors, LLC.Dr. Poma received a Ph.D. in Microbiology and Immunology from the University of North Carolina at Chapel Hill, an M.B.A. from the Leonard N. Stern School of Business and a Bachelor of Science in Biology from the University of North Carolina at Chapel Hill.Company Bio:Calidi Biotherapeutics is a biotechnology company pioneering the development of targeted genetic medicines for cancer and other diseases through its RedTail platform. The company's lead compound, CLD-401, is a systemically delivered oncolytic virus that expresses high levels of IL-15 superagonist only in the tumor microenvironment. The company expects to file an IND to initiate clinical studies for CLD-401 by the end of 2026. The company continues to advance what the RedTail platform can achieve and will be presenting additional data throughout the year.

Men with CF and Infertility: The Science, The Options, The Hope. Pete Proimos is an entrepreneur, a chronic illness advocate, and the founder of the Filotimo Foundation, a nonprofit dedicated to supporting individuals and families affected by cystic fibrosis. Diagnosed with CF as an infant, Pete kept his diagnosis private for decades. It wasn't until his forties that he chose to speak publicly about living with the disease, and that brave decision has changed lives. Pete is married to Annie, and together they are raising three children. His journey into fatherhood is part of what fuels his passion to make sure others with CF understand their options when it comes to building a family. Joining him in this important conversation is Colin Thomas, who leads the Family-Building Program at the Filotimo Foundation. Colin also lives with CF and became a father of five through IVF. In addition to his advocacy work, he serves as Vice President of Operations at IVY Fertility. He brings both professional expertise and deeply personal experience to this discussion, sharing honestly about the challenges and triumphs of becoming a parent with CF. One critical truth we discuss: Men with cystic fibrosis are not infertile because they don't produce sperm. Most are born without a connected vas deferens — the tube that carries sperm — which makes natural conception difficult. But with medical support, including sperm retrieval and IVF, biological fatherhood is often absolutely possible. This episode dives into the mission behind the Filotimo Foundation and the powerful work being done through its infertility and family-building program, work that is giving hope, clarity, and real options to families navigating CF. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Send us Fan MailWelcome to another episode of The Chasing Daylight Podcast! In this episode, Matt makes his triumphant return to the golf course at Mountain Falls following his knee surgery, putting the new joint to the ultimate test. We also dive deep into the latest professional tour news, including Gary Woodland's emotional victory in Houston and the fallout from Tiger Woods' recent DUI arrest. Plus, we talk LPGA history, dive into putting analysis software, and give our top course recommendations for a golf trip to St. George, Utah! Topics Discussed:Matt discusses playing 18 holes at Mountain Falls for the first time with his new knee. He shares that he had zero tentative swings and was driving the ball well. Jeremy gets dialed in on the practice green and range with a new Quantum Max driver and Denali shaft. We recap Gary Woodland's amazing win in Houston and praise his incredible stinger shots. We break down Tiger Woods pleading not guilty to his DUI and stepping away from professional golf. We also discuss the crazy aftermarket hype for his Sunday Red mugshot polo that sold out and is fetching top dollar on eBay. The crew highlights Hyo Joo Kim making LPGA history with multiple 61s. We also preview the upcoming full-field LPGA event at Shadow Creek. Matt shares his new venture into putting analysis using Vertex software. He explains how a session with putting coach Preston Combs inspired him to look deeper into putting metrics. A massive shoutout to Tim Flotte for providing incredible remote golf coaching. Matt details his great experience using the Skillest app to fix his swing basics. We give our top course recommendations for a trip to St. George. Suggestions include Copper Rock, Black Desert, Sand Hollow, and taking a short drive to Wolf Creek. Details on joining the Grassy App using Matt's referral code for a chance to win a Quantum driver. Special thanks to our show sponsor:

Explore how tax management is evolving through technology and strategic innovation to become a key driver of business efficiency and insight.=====Join Michael Bernard from Vertex as he unpacks the latest SAP Insider Benchmark Research on global tax management, revealing how tax departments navigate a rapidly changing landscape. From complex regulatory environments, such as fragmented e-invoicing standards in Europe, to critical pain points like automating tax control frameworks, this episode offers a rich exploration of what's top of mind for CFOs and CIOs. Learn how granular tax data is becoming a strategic asset for sales and marketing, the growing role of managed services amidst workforce shortages, and why the adoption of AI-driven tax automation is still in early stages despite its promising potential. Michael shares memorable stats, including the impact of retirements on CPA talent pools and strategies companies use to overcome compliance time constraints. Perfect for business leaders seeking practical insights on optimizing ERP environments for tax operations with future-ready technology. Listen, learn, and lead the transformation today.⁠⁠⁠⁠⁠⁠⁠Download Episode Transcript⁠⁠⁠⁠⁠⁠⁠Useful Links: ⁠⁠⁠⁠SAP Cloud ERP⁠⁠⁠⁠Follow Us on Social Media!SAP S/4HANA Cloud ERP: ⁠⁠⁠LinkedIn⁠⁠⁠=====Guest: Michael Bernard, Chief Tax Officer of Transaction Tax at VertexMichael Bernard is the Chief Tax Officer of Transaction Tax. In his role, he provides insight and thought leadership around tax department operations, U.S. indirect tax, tax risk management, and tax policy, as well as emerging tax trends. He is also responsible for influencing emerging technologies which meet the continuing regulatory changes of the corporate tax community. He is an executive-level tax attorney with a diverse portfolio of experience in corporate tax, administration, and finance, including a substantive knowledge of U.S. and international tax laws. Prior to joining Vertex, Michael was in various tax leadership roles at Microsoft Corporation for 28 years, the most recent being General Manager & U.S. Tax Counsel. He led teams in the following functional areas: direct and indirect tax controversy, sales and use, business license, property, tax IT, SOX, and telecommunications. He also co-led a corporate taxpayer advocacy group with the Washington Department of Revenue and was a Director on the Board of the Washington Research Council. He has also testified before administrative and lawmakers at both the federal and state level. Michael earned both a J.D. and a Bachelor of Science in Business Administration from Creighton University. He is a part-time lecturer of Law in the LLM program at the University of Washington School of Law. He also served on the board of directors, executive committee, and chaired committees for The Tax Executives Institute (TEI) for nearly 25 years.Host 1: Richard Howells, SAPRichard Howells has been working in the Supply Chain Management and Manufacturing space for over 30 years. He is responsible for driving the thought leadership and awareness of SAP's ERP, Finance, and Supply Chain solutions and is an active writer, podcaster, and thought leader on the topics of supply chain, Industry 4.0, digitization, and sustainability.Follow Richard Howell on ⁠⁠⁠⁠⁠⁠⁠LinkedIn⁠⁠⁠⁠⁠⁠⁠ and ⁠⁠⁠⁠⁠⁠⁠X⁠⁠⁠⁠⁠⁠⁠=====Key Topics: Tax management, ERP, Tax control framework, Automation, Regulatory compliance, Managed services, Workforce skill gap, AI adoption, E-invoicing, Tax analytics

Three decades caring for patients with CF, that's Dr. Alan H. Cohen. His experience continues to shape everything he does today. As a pediatric pulmonologist (board-certified) , he has walked alongside patients through some of their hardest moments, including advanced lung disease and transplantation. Dr. Cohen was previously co-director of the largest pediatric lung transplant program in North America.Those years at the bedside are what ultimately led Dr. Cohen into drug development, where he has spent more than 25 years working to turn scientific innovation into real-world therapies for people who are still waiting for better options. As the Chief Medical Officer of Arcturus Therapeutics, he brings both clinical perspective and urgency to the company's work in mRNA-based therapies for cystic fibrosis and other rare diseases.“Clinical trials aren't just about science, they're about people who are willing to help move the field forward.”In this thoughtful and engaging conversation, Dr. Cohen reflects on how cystic fibrosis care has evolved over the past 35 years, from symptom management to breakthroughs in gene therapy and mRNA technology. Dr. Cohen discusses why clinical trials are essential to progress, especially for rare diseases, and why patient participation plays such a critical role in moving new therapies forward. Dr. Cohen also shares how the strength of the CF community continues to inspire his work, offering both realism and hope for the future of CF research.You'll also hear more about the personal side of this wonderful scientist! The Arcturus team packed Bonnell Foundation Hospital Bags with comfort products for caregivers, and CF adults for California CF Clinics. #teamworkClinical trials are an important step to understand whether a medicine works for its intended purpose.  Please see our active clinical trials below. For any questions email:  Community@ArcturusRx.com. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

I've known Julie McCaffrey for years. She lives about 40 minutes from me, in Romeo, Michigan. Julie and her husband, Curtis, are raising four daughters, and their oldest, Jenna—now 20—lives with cystic fibrosis.What still makes me smile is how Julie and I were connected long before we ever met through the CF community… and we had no idea. We worked in the same building, in the same industry, at the same time. Both of us were in radio. I was a news reporter at WWJ, while Julie was a producer at WYCD. Even our podcast editor worked at another station in that very same building. Proof that sometimes the universe plants people in your orbit long before it tells you why.Julie's career path reflects both her curiosity and her compassion. She's worked in radiology, orthopedics, and labor and delivery. She's supported students as a paraprofessional in an elementary school and worked in a group home for adults with intellectual disabilities. Today, she works at Target—and genuinely loves it. Wherever she goes, she brings the same energy: presence, kindness, and care.At the heart of everything Julie does is a simple but powerful mission—to spread joy. She is deeply passionate about mental health advocacy, especially within the cystic fibrosis community. And despite the very real financial strain that comes with healthcare and insurance challenges, Julie continues to show up with an unwaveringly positive spirit. Not a performative positivity—but a grounded, generous kind that makes people feel seen.If you take just one thing from Julie today, let it be this:You are brilliant.You are beautiful.And you can do anything.(Suicide was discussed in this episode. Anyone needing help can call or text #988).  Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Halfway through the show STRIGGA had an unexpected and unfortunate situation where is X (formerly known as Twitter) account @STRIGGA was hacked. Therefore Dylan went solo for the last half or so after the 42 minute mark. We apologize for the inconvenience and will make it up one day!   On the return effort with Strig back from WxW we talk a bit about the state of the scene as well as an unexpected foray into the US and even Australian indies, but it leads us to Dylan's pick for a promotion to watch: Osaka Pro! We talked about the recent Tag Festival and the great storyline with VerteX and Rogue Nation, with great vibes of the promotion in particular. We then talk about the significance of Shinjuku FACE and how it will effect multiple companies going forward when it closes, along with the history of the building itself and Strig's past visits there.   After Dylan takes over solo he does a mini-run through of multiple big stories right now including:   - NJPW New Japan Cup - Stardom Cinderella Tournament - AJPW Champion Carnival Blocks - NOAH's 3.8 show featuring 2 great matches and a lot of rookies! - DG in Disarray and KAI vs. Kikuta being the next Dream Gate match   For more coverage of Japanese wrestling, and wrestling past and present please check out our Patreon for literally 1000s of hours of audio and written content as well, including the brand new EL Weekly Newsletter: https://www.patreon.com/easternlariat    Follow us on Twitter/X:     https://www.twitter.com/easternlariat    https://www.twitter.com/strigga       https://www.twitter.com/viva_zero   Follow us on BlueSky: @easternlariat.bsky.social @vivazero.bsky.social @strigga.bksy.social   Follow us on IG: https://www.instagram.com/easternlariat   If you would like more info check out Ruth (@ruthisanotter) and her great coverage of the company and it's Units, check her out on Twitter/X as well as their fantastic article on the subject: https://sixtyminutedraw.com/guide-to-osaka-pro-factions

“What if a blood draw didn't have to feel terrifying, Abby Rose is a child life specialist. And if you have never taken advantage of all they have to offer when your child is hospitalized, you're going to want to connect with them after you listen or watch this podcast!The North American Cystic Fibrosis Conference is one of those places you attend to learn—but it's also a place where you meet people who quietly leave a lasting mark. One of those people is Certified Child Life Specialist Abby Rose.Abby works at Seattle Children's Hospital, supporting both the Cystic Fibrosis program and Pediatric Hemodialysis. Originally from Wisconsin, she earned her bachelor's degree in Psychology and Family Studies from the University of Wisconsin–Eau Claire, followed by a master's degree in Child Life from Edgewood College.In her role, Abby focuses on outpatient care, working closely with children and families to create individualized coping plans. She supports kids through procedures many of us take for granted—blood draws, throat swabs, vaccinations, while also helping families navigate pill swallowing, treatment tolerance, sibling support, and the everyday challenges that can feel overwhelming in CF care.People like Abby made a profound difference for kids like one of my daughters—children who are frightened by procedures or don't fully understand what's about to happen to them. Child Life Specialists play a critical role in hospital settings, helping children feel safer, more informed, and more in control during some of their most vulnerable moments.Today, I'm excited to talk with Abby about the work she does—and why it matters so deeply.In our conversation, we'll explore:The Beads of Courage program and why it's so meaningful to children and familiesWhy Abby is such a strong advocate for transparency, open communication, and the rights of patients and familiesWhat draws her personally to Child Life work, and why she believes in it so deeplyAnd some of the “tricks of the trade”—the practical tools and techniques she uses to help kids feel calmer and more cooperative during procedures like blood drawsThis is a conversation about care, trust, and the people who help make hard moments just a little bit easier. Please like, subscribe, and comment on our podcasts!Please consider making a donation: https://thebonnellfoundation.org/donate/The Bonnell Foundation website:https://thebonnellfoundation.orgEmail us at: thebonnellfoundation@gmail.com Watch our podcasts on YouTube: https://www.youtube.com/@laurabonnell1136/featuredThanks to our sponsors:Vertex: https://www.vrtx.comViatris: https://www.viatris.com/enRead us on Substack: https://substack.com/@lstb?utm_campaign=profile&utm_medium=profile-pageWatch our trailer of Embracing Egypt: https://youtu.be/RYjlB25Cr9Y

Hey Diabuddy thank you for listening to show, send me some positive vibes with your favorite part of this episode.What would life look like if Type 1 diabetes suddenly… stopped controlling every decision you make?In this episode of The Healthy Diabetic Podcast, Coach Ken sits down with Katie Beth Hand, a participant in the groundbreaking Eledon clinical trial, which is exploring a potential functional cure for Type 1 diabetes through islet cell transplantation and targeted immune therapy.Katie Beth shares her powerful story—from her unexpected diagnosis at age 26 to becoming Patient 9 in the Eledon trial, a study that has allowed several participants to live without insulin.Together, Ken and Katie explore the emotional reality of diagnosis, the challenges of navigating diabetes as an adult, and the excitement surrounding emerging research that may redefine the future of diabetes treatment.This conversation goes beyond the science. It highlights the lived experience of diabetes and the hope that real progress is finally being made toward a cure.

We're joined by droqen (The End of Gameplay, Starseed Pilgrim), Darius Kazemi (Tiny Subversions, Harvard Applied Social Media Lab), and Tara Macalister (mathematician, composer) to discuss Vertex Dispenser, the second game in our year-long exploration of the work of Michael Brough. Next Month: Kompendium Audio edited by Dylan Shumway. Discussed in this episode: Vertex Dispenser https://store.steampowered.com/app/102400/Vertex_Dispenser/ Michael Brough's Website https://www.smestorp.com/ Four color theorem https://en.wikipedia.org/wiki/Four_color_theorem Graph coloring https://en.wikipedia.org/wiki/Graph_coloring  Starcraft II https://starcraft2.blizzard.com/en-us/ Splatoon https://splatoon.nintendo.com/  Dota 2 https://www.dota2.com/home  Droqen's rare color graph/explanation https://discord.com/channels/690388280767807518/1442554518092120186/1465039921147412510  lots of michael brough games https://smestorp.itch.io/lots-of-michael-brough-games  The Sense of Connectedness https://forums.tigsource.com/index.php?topic=16151.0  Kompendium https://mightyvision.blogspot.com/2012/06/kompendium.html The End of Gameplay https://droqen.itch.io/the-end-of-gameplay Utopia Clicker https://tinysubversions.com/game/utopia/ A Jackpot of Skulls https://brainfruit.studio/games/jackpot _update() Jam https://adamatomic.itch.io/update-jam   https://secretlives.games/  https://discord.gg/tslog https://www.patreon.com/tslog https://www.youtube.com/eggplantshow